Lymphocyte predominant Hodgkin Disease: Clinico-pathologic features and results of treatment—The pediatric oncology group experience

Publisher Website
Google Scholar
Abstract
Purpose In this report, the Pediatric Oncology Group (POG) experience with lymphocyte predominant Hodgkin Disease (LPHD) in children is reviewed. Materials and Methods From 1984–1993, the POG conducted 3 clinical trials for advanced stage HD and 2 for early stage HD. There were 26 cases of LPHD in 613 patients in these trials. Patients' ages ranged from 3.1–17.8 years (mean of 12.9 years). There was a marked male predominance. Results Histologic subtypes were 17 nodular, 8 diffuse pattern; 1 was indeterminant. The sites involved at diagnosis were primarily the peripheral lymph nodes. Fourteen patients had stage (S) I disease; 9 had SII; 3 had SIII; there was no SIV disease. Only 4 of 26 patients had B symptoms. All 26 patients achieved complete remission, 10 with radiotherapy, 6 with chemotherapy and 10 with combined modality therapy. Treatment was not uniform since patients were registered on different protocols. Event‐free survival after 5 years was 86.5 percent. Two patients developed and succumbed to large cell, T‐cell type, non‐Hodgkin lymphoma (NHL). Conclusions Optimal treatment for LPHD should focus on efforts to limit the risk of second malignancy. Med. Pediatr. Oncol. 29:519–525, 1997.